Enanta Pharmaceuticals SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 28, 2026, 7:14 a.m. ETView on SEC.gov
Departure/appointment of directors or officers · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedEnanta Pharmaceuticals Announces Planned Retirement of CEO Jay R. Luly by February 1, 2027 and Names Tara L. Kieffer Chief Operating Officer
8-KAug. 10, 2026, 4:05 p.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits